Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06413537
PHASE2

Study of SPG601 in Adult Men With Fragile X Syndrome

Sponsor: Spinogenix

View on ClinicalTrials.gov

Summary

This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of SPG601 in adult men with Fragile X syndrome.

Official title: A Phase 2a, Randomized, Double-Blinded, Study Evaluating the Neurophysiologic vs Clinical Effects of Single-Dose SPG601 and Placebo in Adult Men With Fragile X Syndrome

Key Details

Gender

MALE

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2024-07-05

Completion Date

2024-12-31

Last Updated

2026-05-26

Healthy Volunteers

No

Interventions

DRUG

SPG601

synthetic small molecule

DRUG

Placebo

Placebo

Locations (1)

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States